Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Novartis is rolling out new data that build on its case for the company’s blockbuster hopeful RTH258, an investigational therapy that might carve away a considerable chunk of Regeneron’s $5 billion Eylea franchise if approved.